| Description | TLR7/8 agonist 9 (Compound 25a), exhibiting EC50 values of 40 nM and 23 nM for hTLR7 and hTLR8 respectively, demonstrates anti-tumor properties and enhances the efficacy of PD-1/PD-L1 blockade treatments. This compound is utilized in cancer immunotherapy research [1]. |
| molecular weight | 366.46 |
| Molecular formula | C20H26N6O |
| CAS | 2649170-17-0 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |